LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast Cancer (LINE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01561443
Recruitment Status : Completed
First Posted : March 23, 2012
Last Update Posted : January 11, 2016
Information provided by (Responsible Party):

Brief Summary:
This is the first study focused on features/stereotypes of the first and second-line treatment patterns in Russia, comparison of different treatments, and determination of effective hormone treatment patterns in real-life practice with evaluation of pharmacoeconomic aspects. Study LINE is designed for collection of data on clinical effectiveness of second-line hormone treatment and quality of life in patients with breast cancer(BC).

Condition or disease
Local Advanced or Metastatic Postmenopausal Breast Cancer

Detailed Description:
LINE: Treatment patterns in postmenopausaL women wIth hormone receptor positive breast caNcEr

Study Type : Observational
Actual Enrollment : 153 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast Cancer
Study Start Date : May 2012
Actual Primary Completion Date : January 2015
Actual Study Completion Date : January 2015

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Collection of data of routine regimens of hormone therapy in postmenopausal women with hormone receptor-positive, locally advanced or metastatic breast cancer [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Quality of life (QoL): the extent of reduction in QoL deficit from 1 visit [ Time Frame: 2 years ]
  2. The extent of reduction anxiety inventory [ Time Frame: 2 years ]
  3. Effectiveness: Tumor regression; number of patients with complete response (CR), partial response (PR) or stable disease [ Time Frame: 2 years ]
  4. Historical data analysis: treatment patterns effectiveness, duration of the adjuvant or first-line hormone treatment [ Time Frame: 2 years ]
  5. Response duration [ Time Frame: 2 years ]
  6. Performance status (ECOG) [ Time Frame: 2 years ]
  7. Co-morbidities and relevant historical data [ Time Frame: 2 years ]
  8. The information on spontaneous office visit to oncologist or hospitalization including reasons, diagnosis, days of hospitalization, procedures and concomitant medication changes will be collected. [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
hormone positive, postmenopausal breast cancer

Inclusion Criteria:

  • Postmenopausal women with hormone receptor-positive breast cancer:
  • Recurrence after the adjuvant hormone therapy;
  • Or initially inoperable locally advanced or metastatic breast cancer progressed after the first line hormone therapy;
  • Ability to read and write and complete questionnaires Provision of written informed consent
  • Patients who have already been prescribed therapy with the above-mentioned lines and who can continue on the prescribed therapy in the investigator's opinion according to his/her regular clinical practice and cure

Exclusion Criteria:

  • As per study design, to ensure high validity of data and to obtain accurate information on real-life practice,
  • Patients currently participating in other clinical studies will not be included in this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01561443

Russian Federation
Research Site
Chita, Russian Federation
Research Site
Irkutsk, Russian Federation
Research Site
Kaluga, Russian Federation
Research Site
Kazan, Russian Federation
Research Site
Kemerovo, Russian Federation
Research Site
Khanty-Mansiysk, Russian Federation
Research Site
Krasnodar, Russian Federation
Research Site
Krasnoyarsk, Russian Federation
Research Site
Moscow, Russian Federation
Research Site
Omsk, Russian Federation
Research Site
Perm, Russian Federation
Research Site
S-Petersburg, Russian Federation
Research Site
Samara, Russian Federation
Research Site
Tula, Russian Federation
Research Site
Tver, Russian Federation
Research Site
Ufa, Russian Federation
Research Site
Vladivostok, Russian Federation
Research Site
Volgograd, Russian Federation
Research Site
Yaroslavl, Russian Federation
Sponsors and Collaborators
Study Director: Alexey Stepanov, Prof. AstraZeneca
Principal Investigator: Maria Konstantinova, Prof Russian Oncology Scientific Center
Principal Investigator: Sergey Gutorov, Prof. Russian Oncology Scientific Center
Principal Investigator: Marina Stenina, PhD Surgery Institute named after A.V. Vishnevskiy

Additional Information:
Responsible Party: AstraZeneca Identifier: NCT01561443     History of Changes
Other Study ID Numbers: NIS-ORU-XXX-2011/1
First Posted: March 23, 2012    Key Record Dates
Last Update Posted: January 11, 2016
Last Verified: January 2016

Keywords provided by AstraZeneca:
Breast cancer,
hormone positive,

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs